Safety evaluation of adalimumab in immune-mediated inflammatory disorders: a rheumatological point of view.

@article{Duquenne2019SafetyEO,
  title={Safety evaluation of adalimumab in immune-mediated inflammatory disorders: a rheumatological point of view.},
  author={Laurence Duquenne and Hanna L Gul and Paul Emery},
  journal={Expert opinion on drug safety},
  year={2019},
  volume={18 1},
  pages={
          11-19
        }
}
INTRODUCTION Immune-mediated inflammatory disorders (IMIDs) are systemic conditions which arise secondary to complex immune mechanism defects and can affect many organs. While previous therapies based on steroids and immunosuppressive agents had a poor risk/benefit balance, TNFα-specific inhibitors such as adalimumab have revolutionized the course of many diseases and patient outcomes. However, concerns were raised regarding the increased risk of infectious diseases and neoplasia due to… CONTINUE READING
BETA

Similar Papers

Loading similar papers…